India’s pharmaceutical industry is poised for robust revenue growth of 7-9% in FY26, driven by domestic and European markets, despite facing challenges in the US market. Factors such as enhanced rural distribution, new product launches domestically, and increased R&D investments are key drivers of this growth trajectory.
ICRA’s recent sector outlook forecasts a significant revenue increase for India’s pharmaceutical industry in FY26, underpinned by an estimated 8-10% growth in the domestic market and a 10-12% expansion in Europe. This growth is expected to be tempered by a more modest 3-5% increase in the US market following a strong 10% rise in FY25.
Senior Vice President & Co-Group Head of ICRA, Kinjal Shah, emphasized that the growth momentum in the domestic market will be supported by factors such as sales force expansion, enhanced medical representative productivity, deeper rural market penetration, and the introduction of new products. These initiatives are crucial in sustaining the projected revenue growth.
Government measures like GST exemptions and reductions in select lifesaving drug rates are anticipated to enhance healthcare affordability in India. Conversely, the US market poses challenges due to ongoing FDA scrutiny and pricing pressures, necessitating a cautious approach.
Despite these challenges, Indian pharmaceutical companies are intensifying their R&D efforts to develop complex molecules and specialty products, contributing to the projected revenue growth in Europe. While pharmaceuticals currently enjoy exemption from tariffs imposed by the US, future export dynamics remain at risk due to these trade measures.
Drive in Domestic Market Growth:
– Enhanced rural distribution and new product launches are expected to drive an 8-10% growth in the domestic market.
– Improved medical representative productivity and government initiatives like GST exemptions will further bolster this growth trajectory.
Focus on European Expansion:
– The Indian pharmaceutical industry is projected to achieve a 10-12% revenue growth in Europe in FY26, driven by investments in developing complex molecules and specialty products.
– This European expansion indicates a strategic shift towards diversifying revenue streams and reducing reliance on the US market.
R&D Investments and Innovation:
– Increased focus on R&D investments to develop innovative products is crucial for sustaining growth amidst challenges in various markets.
– Developing complex molecules and specialty products not only fuels growth in Europe but also strengthens the industry’s competitiveness globally.
In conclusion, the Indian pharmaceutical industry’s resilience and growth prospects in the face of challenges in the US market are underpinned by strategic initiatives in domestic expansion, European market penetration, and innovation through R&D investments. By capitalizing on these drivers and navigating market complexities effectively, Indian pharmaceutical companies are poised to continue their upward trajectory, demonstrating adaptability and long-term sustainability in a dynamic global landscape.
Read more on devdiscourse.com